AYA is flashing a sharp contradiction. The stock has rallied 23% over the past month to AUD 4.95. Short sellers have been cutting positions. Yet the cost to borrow has erupted to levels that suggest someone urgently wants to bet against it.
The borrow story is the standout this week. Cost to borrow has exploded to 25.1% annualised — up more than 3,300% in a single week — after sitting near zero throughout late April. That is an extraordinary move. The surge points to a sudden surge in demand for borrows with far fewer shares available to lend at the margin, even as the lending pool itself remains broadly well-stocked. For context, availability for AYA is around 720% of short interest — meaning there are roughly seven shares available to borrow for every one already lent — so this is not a structural supply crisis. It is a pricing event: someone (or multiple parties) has been willing to pay a steep premium to get short exposure, driving the rate sharply higher.
Short interest tells the opposite story, and that contrast matters. Estimated short interest has fallen nearly 10% over the past week to just 1.1% of free float — a low reading for any stock. The ORTEX short score is a mild 33, easing from the mid-34s seen earlier in May. Days to cover is a modest 3.75. None of these numbers describe a stock with meaningful crowded-short pressure. The borrow cost spike is therefore not a function of existing shorts being squeezed — it looks more like fresh demand hitting a temporarily illiquid lending desk on a small-cap name.
Institutional ownership adds useful colour here. Regal Partners holds roughly 11% of the company. Wilson Asset Management built a position above 6% in late January. UBS Asset Management trimmed by around 789,000 shares as recently as mid-May, bringing its stake to just under 5%. The UBS trim is the most recent institutional move, and it came while the stock was in the middle of its one-month rally. Bernard Ridgeway added 500,000 shares in April. That combination — a fund manager reducing while a director adds — gives no clean directional read on near-term sentiment among those closest to the stock.
On the analyst side, the consensus is a buy with a mean price target of AUD 6.14 against the current price of AUD 4.95, implying roughly 24% upside to target. Bell Potter reiterated its Buy rating on 1 May. Three analysts cover the name. The EPS forward estimate momentum rank is in the 92nd percentile — among the strongest in the universe — and analyst recommendation divergence also ranks 92nd, suggesting the buy consensus is unusually unified. The price-to-book multiple has expanded about 16% over the past 30 days to 9.7x, consistent with the re-rating in price. The EV/EBITDA is deeply negative, as expected for a pre-profit AI software company burning cash to grow. A Stockhead profile published mid-May framed AYA as a company "betting on AI to outsmart heart disease," which neatly captures the bull case: regulatory approval and commercial traction for its cardiac AI software on the ASX.
The earnings history provides a useful read on how the stock typically behaves around announcements. The most recent event on 26 May delivered a -1.1% one-day move. The May 1 print produced a +12.1% one-day jump. The February 25 release added nearly 5% on the day. Three of the last four events produced positive day-one reactions. Among correlated ASX peers, ONE added 5.9% on the week in line with AYA's 4.4%, while PME rose 3.4%. M7T was the week's standout, gaining 8.2% in a single session. The peer moves suggest broader appetite for ASX health-tech names this week rather than an AYA-specific catalyst.
The borrow cost spike is the number to watch: whether it normalises quickly back toward single digits — as has happened before in AYA's history — or holds and pushes higher will indicate whether the demand for short exposure was a brief episode or the start of a more sustained positioning shift against the rally.
See the live data behind this article on ORTEX.
Open AYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
